| Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients (NCT01723943) | University of Washington | 2009-03-01 |
| Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer (NCT00572728) | National Cancer Institute (NCI) | 2008-12-01 |
| Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant (NCT00795769) | Fred Hutchinson Cancer Center | 2008-08-08 |
| Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer (NCT00679029) | University of Nebraska | 2008-05-02 |
| Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (NCT00618657) | University of California, Irvine | 2008-02-01 |
| Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery (NCT00559507) | National Cancer Institute (NCI) | 2007-10-01 |
| Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer (NCT00513695) | University of Washington | 2007-06-01 |
| Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer (NCT00470301) | National Cancer Institute (NCI) | 2007-04-01 |
| Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer (NCT00416715) | University of Washington | 2006-10-01 |
| Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers (NCT01043003) | City of Hope Medical Center | 2006-08-01 |
| Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer (NCT00368875) | National Cancer Institute (NCI) | 2006-07-01 |
| Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (NCT00408681) | Fred Hutchinson Cancer Center | 2006-06-01 |
| ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment (NCT00425672) | University of Washington | 2005-09-01 |
| Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer (NCT00096109) | National Cancer Institute (NCI) | 2005-09-01 |
| Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen (NCT00118157) | National Cancer Institute (NCI) | 2005-05-01 |
| Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer (NCT00082810) | National Cancer Institute (NCI) | 2004-03-01 |
| Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer (NCT00343109) | University of Washington | 2004-03-01 |
| Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer (NCT00063934) | National Cancer Institute (NCI) | 2003-05-01 |
| Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (NCT00060372) | National Cancer Institute (NCI) | 2003-04-01 |
| Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer (NCT00070057) | National Cancer Institute (NCI) | 2003-04-01 |
| Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer (NCT00049114) | National Cancer Institute (NCI) | 2003-02-01 |
| Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer (NCT00436254) | University of Washington | 2001-10-01 |
| Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic (NCT00003440) | National Cancer Institute (NCI) | 1998-07-01 |
| Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer (NCT00080613) | Robert H. Lurie Cancer Center | |